Literature DB >> 8219610

Induction of discriminant function concerning postoperative local recurrence or distant metastasis in 589 patients with differentiated thyroid cancer.

Y Mori1, K Takaya, Y Miyata, S Satomi, T Sasaki, Y Taguti, S Mori, Y Sekita, N Matoba, H Kurihara.   

Abstract

For the purpose of predicting postoperative local recurrence and/or distant metastasis in differentiated thyroid cancer, a discriminant analysis was done. To assess the reliability of this method and the induced function, simulation was done by using random samples under various conditions. Simulation revealed that the results obtained by this method were relatively stable. The discriminant functions Z1 and Z2 were induced, which are required at many hospitals. If the ratio of recurrence is less than 1:8 in a hospital, function Z1 should be applied. If the ratio is 1:10, function Z2 should be applied. Z1 = -(sex x 2.104) + (age x 0.032) - (diameter of tumor x 0.033)-(site of tumor x 0.871) - (histology x 0.393) + 0.249 (discriminant boundary 0.451) Z2 = -(sex x 1.967) + (age x 0.018) + (diameter of tumor x 0.025) - (site of tumor x 0.646) + (histology x 0.014) - (local invasion x 0.840) - (lymph node metastasis x 0.009) + (operation x 0.364) - (lymph node dissection x 0.235) + 1.058 (discriminant boundary 0.400). In an internal check, sensitivity was 78%, specificity 64%; and false-negative rate 5%. In an external check, sensitivity was 68%, specificity 93%, and false-negative rate 9%. In the actual application to hospitals, sensitivity was 58% to 100%, specificity 47% to 63%, and false-negative rate 0% to 16%. In clinical usage, a high sensitivity and low false-negative rate are required. These results fulfilled this condition.

Entities:  

Mesh:

Year:  1993        PMID: 8219610     DOI: 10.1007/bf00311619

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  13 in total

1.  FOLLOW-UP STUDY OF THYROID CANCER TREATED BY UNILATERAL LOBECTOMY.

Authors:  R G ROSE; M P KELSEY; W O RUSSELL; M L IBANEZ; E C WHITE; R L CLARK
Journal:  Am J Surg       Date:  1963-09       Impact factor: 2.565

2.  Multicentricity of papillary adenocarcinoma of the thyroid: influence on treatment.

Authors:  B M BLACK; T A KIRK; L B WOOLNER
Journal:  J Clin Endocrinol Metab       Date:  1960-01       Impact factor: 5.958

3.  Changing end results in patients with papillary carcinoma of the thyroid.

Authors:  G Crile
Journal:  Surg Gynecol Obstet       Date:  1971-03

4.  Papillary thyroid carcinoma: the impact of therapy in 576 patients.

Authors:  E L Mazzaferri; R L Young; J E Oertel; W T Kemmerer; C P Page
Journal:  Medicine (Baltimore)       Date:  1977-05       Impact factor: 1.889

5.  Differentiated cancers of the thyroid: course after treatment with special reference to frequency and chronology of the first relapse for 470 treated patients.

Authors:  P Gardet; C Parmentier; R Gerard-Marchant; C L'Heritier; B Caillou; W Cukersztein; M Tubiana
Journal:  Ann Radiol (Paris)       Date:  1977 Nov-Dec

6.  Prognostic features of thyroid cancer. A long-term followup of 68 cases.

Authors:  M A Russell; E F Gilbert; W F Jaeschke
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

7.  Changing clinical, pathologic, therapeutic, and survival patterns in differentiated thyroid carcinoma.

Authors:  B Cady; C E Sedgwick; W A Meissner; J R Bookwalter; V Romagosa; J Werber
Journal:  Ann Surg       Date:  1976-11       Impact factor: 12.969

8.  Is the EORTC prognostic index of thyroid cancer valid in differentiated thyroid carcinoma? Retrospective multivariate analysis of differentiated thyroid carcinoma with long follow-up.

Authors:  J Tennvall; A Biörklund; T Möller; J Ranstam; M Akerman
Journal:  Cancer       Date:  1986-04-01       Impact factor: 6.860

9.  Prognosis in thyroid carcinoma.

Authors:  K O Franssila
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

10.  Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients.

Authors:  E L Mazzaferri; R L Young
Journal:  Am J Med       Date:  1981-03       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.